Tekla Capital Management LLC Fate Therapeutics Inc Transaction History

Tekla Capital Management LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 13, 2022	SELL	$29.67 - $60.28 $1.22 Million - $2.48 Million	-41,075 Reduced 56.48%	31,652 $1.23 Million
Q2 2021 Aug 13, 2021	SELL	$67.25 - $92.52 $5.22 Million - $7.18 Million	-77,616 Reduced 51.63%	72,727 $6.31 Million
Q1 2021 May 14, 2021	SELL	$72.16 - $117.4 $1.15 Million - $1.88 Million	-15,974 Reduced 9.6%	150,343 $12.4 Million
Q4 2020 Feb 12, 2021	SELL	$38.09 - $100.95 $1.95 Million - $5.16 Million	-51,145 Reduced 23.52%	166,317 $15.1 Million
Q3 2020 Nov 13, 2020	BUY	$30.41 - $40.5 $966,733 - $1.29 Million	31,790 Added 17.12%	217,462 $8.69 Million
Q2 2020 Aug 13, 2020	BUY	$20.21 - $35.23 $404,200 - $704,599	20,000 Added 12.07%	185,672 $6.37 Million
Q3 2019 Nov 13, 2019	BUY	$15.47 - $22.5 $2.19 Million - $3.18 Million	141,293 Added 579.57%	165,672 $2.57 Million
Q2 2019 Aug 14, 2019	BUY	$15.61 - $20.44 $380,556 - $498,306	24,379 New	24,379 $495,000

167

101M

41.3K

15.9K

Ticker FATE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 97,000,304
Market Cap $99.9M
Description
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell...

Get notified when there are updates to the investment portfolio of Tekla Capital Management LLC, based on Form 13F filings with the SEC.

Stay updated on Tekla Capital Management LLC with notifications on news.